News Releases

Jun 24, 2020
Sangamo Announces R&D Organization Changes
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 24, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization. Going forward, research and development will each be managed as separate functions. A search for a Head of Development is underway.
Additional Formats
PDF Version
Jun 18, 2020
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
— Dosing of the first patient in the pivotal Phase 3 study anticipated in second half of 2020 — NEW YORK & BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 18, 2020-- Pfizer Inc. (NYSE:PFE)   and   Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data
Additional Formats
PDF Version
May 07, 2020
Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting
BRISBANE, Calif. --(BUSINESS WIRE)--May 7, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and safety concerns related to the coronavirus
Additional Formats
PDF Version
Displaying 1 - 10 of 21